Vardenafil (Levitra/Staxyn) and Hormonal Contraceptives: Is There a Drug Interaction?

Why This Combination Comes Up in Clinical Practice

Vardenafil is a phosphodiesterase type 5 (PDE5) inhibitor prescribed for erectile dysfunction, while hormonal contraceptives contain synthetic estrogens and/or progestins used for pregnancy prevention. The question of interaction arises because both drug classes undergo hepatic metabolism involving cytochrome P450 enzymes, specifically CYP3A4. Patients and prescribers sometimes flag this overlap as a potential concern.

The scenario is less common than other PDE5 inhibitor interaction queries, since vardenafil is prescribed to individuals with erectile dysfunction and hormonal contraceptives are used by their sexual partners. Direct co-administration in the same patient is uncommon but does occur in transgender women or in off-label contexts. Even in those cases, available pharmacokinetic data and the FDA-approved labeling for both drug classes indicate no clinically significant interaction requiring dose modification or avoidance [1][2].

The FDA label for vardenafil (Levitra) does not list hormonal contraceptives among its drug interactions, and combined oral contraceptive labels do not flag PDE5 inhibitors [1][3]. This absence is meaningful. The FDA requires manufacturers to disclose interactions identified during clinical development, and no signal emerged during the vardenafil registration program, which enrolled over 8,000 subjects across multiple phase III trials [4].

Mechanism: How These Drugs Are Metabolized

Both vardenafil and the estrogen component of combined hormonal contraceptives (typically ethinyl estradiol) interact with CYP3A4, but in different ways and at different magnitudes. Understanding this distinction explains why the combination is pharmacokinetically benign.

Vardenafil undergoes extensive first-pass hepatic metabolism. CYP3A4 is the primary enzyme responsible for its biotransformation, with CYP3A5 and CYP2C9 contributing as minor pathways [1]. The drug's oral bioavailability is approximately 15%, and its elimination half-life is 4 to 5 hours. Strong CYP3A4 inhibitors like ketoconazole and ritonavir increase vardenafil area under the curve (AUC) by 10-fold and 49-fold, respectively, necessitating significant dose reductions [1].

Ethinyl estradiol (EE), the estrogen in most combined oral contraceptives, is metabolized by CYP3A4 through 2-hydroxylation [5]. EE also acts as a weak, mechanism-based inhibitor of CYP3A4, meaning it can modestly reduce the enzyme's activity over time [6]. The magnitude of this inhibition is small. Studies in healthy volunteers show that oral contraceptives containing 30 to 35 mcg of EE increase the AUC of CYP3A4 substrates by roughly 15 to 30% on average [6]. That figure is far below the threshold that triggers dose adjustment for vardenafil, which the FDA label sets at the level of moderate CYP3A4 inhibitors (e.g., erythromycin increases vardenafil AUC by 4-fold) [1].

Progestin-only contraceptives (minipills, hormonal IUDs, the etonogestrel implant) have even less CYP3A4 interaction potential. Levonorgestrel, norethindrone, and etonogestrel are CYP3A4 substrates but are not meaningful inhibitors of the enzyme at therapeutic concentrations [7]. No published study has reported any pharmacokinetic change in PDE5 inhibitor exposure from progestin-only methods.

Pharmacodynamic Considerations

Beyond metabolism, a drug interaction can occur when two medications affect the same physiological system in ways that amplify or oppose each other's effects. This is called a pharmacodynamic (PD) interaction.

Vardenafil works by inhibiting PDE5, which increases cyclic guanosine monophosphate (cGMP) in vascular smooth muscle, causing vasodilation primarily in the corpus cavernosum [1]. Its main systemic hemodynamic effect is a mild, transient decrease in blood pressure (5 to 10 mmHg systolic) [4].

Hormonal contraceptives exert their effects through suppression of the hypothalamic-pituitary-ovarian axis and have no direct action on the nitric oxide/cGMP pathway [3]. Estrogen does have vascular effects, including upregulation of endothelial nitric oxide synthase, but at the low doses used in modern contraceptives (20 to 35 mcg EE), these effects are subclinical and do not produce measurable changes in systemic blood pressure in most users [8].

There is no overlapping PD mechanism that would produce additive hypotension, QTc prolongation, or other adverse hemodynamic outcomes from the combination. The only PD interaction flagged on the vardenafil label involves nitrates (contraindicated), alpha-blockers (caution), and class IA/III antiarrhythmics (QTc concern) [1]. Hormonal contraceptives fall into none of these categories.

What the FDA Labels Say

The vardenafil (Levitra) prescribing information lists the following drugs and drug classes under "Drug Interactions" [1]:

• Nitrates (contraindicated)
• Alpha-adrenergic blockers (dose adjustment required)
• CYP3A4 inhibitors: ketoconazole, itraconazole, ritonavir, indinavir, erythromycin (dose reduction required)
• Class IA and III antiarrhythmics: quinidine, procainamide, amiodarone, sotalol (avoid)

Hormonal contraceptives are absent from this list. Similarly, the FDA label for combination oral contraceptives (e.g., the norgestimate/ethinyl estradiol label) does not list PDE5 inhibitors in its interaction section [3]. The label does note interactions with strong CYP3A4 inducers (rifampin, certain anticonvulsants) that can reduce contraceptive efficacy, but vardenafil is neither a CYP3A4 inducer nor inhibitor [1][3].

For Staxyn (vardenafil orally disintegrating tablet), the bioavailability differs from film-coated Levitra, but the metabolic pathway is identical [9]. The same absence of hormonal contraceptive interaction applies. The maximum dose of Staxyn is 10 mg per day, compared to 20 mg per day for Levitra tablets, and this difference is due to the ODT formulation's higher bioavailability, not any interaction concern [9].

Specific Scenarios Worth Addressing

Transgender women on estrogen therapy and vardenafil. Some transgender women take supraphysiologic estrogen doses (e.g., estradiol valerate 20 mg IM every two weeks) alongside PDE5 inhibitors for sexual function. Estradiol (as opposed to ethinyl estradiol) is metabolized primarily by CYP1A2 and CYP3A4 but is not a mechanism-based CYP3A4 inhibitor [10]. Even at higher doses, 17-beta estradiol is not expected to alter vardenafil pharmacokinetics to a clinically relevant degree. No published case report or pharmacokinetic study has identified an interaction in this population.

Extended-cycle or continuous oral contraceptives. Regimens that eliminate the placebo week (e.g., 84/7 or 365-day continuous dosing) maintain steady-state EE levels without interruption. The weak CYP3A4 inhibition from EE is already accounted for at steady state. Switching from cyclic to continuous OCP use does not create a new interaction risk with vardenafil.

Vaginal rings and transdermal patches. The NuvaRing delivers etonogestrel and ethinyl estradiol, while the Xulane patch delivers norelgestromin and EE. Both achieve lower peak EE levels than oral formulations because they bypass first-pass hepatic metabolism [11]. Lower hepatic EE exposure means even less CYP3A4 inhibition, making an interaction with vardenafil even less plausible.

Progestin-only IUDs (Mirena, Kyleena, Liletta). These devices deliver levonorgestrel locally to the uterus with minimal systemic absorption. Serum levonorgestrel levels from the 52 mg IUD are approximately 150 pg/mL, roughly 1/10th the level seen with oral levonorgestrel [12]. No hepatic CYP interaction is expected at these concentrations.

When to Be Cautious: Real Interactions to Watch

While vardenafil and hormonal contraceptives do not interact with each other, both drugs do interact with other medications that patients may be taking concurrently. Prescribers should screen for these genuine interactions rather than focusing on the benign OCP/PDE5 inhibitor combination.

Vardenafil interactions that matter:

• Nitrates (nitroglycerin, isosorbide): absolute contraindication due to severe hypotension risk [1]
• Strong CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin): require vardenafil dose reduction to 2.5 mg per 24 hours [1]
• Alpha-blockers (tamsulosin, doxazosin): initiate vardenafil at 5 mg, monitor for orthostatic hypotension [1]
• QTc-prolonging drugs: vardenafil causes dose-dependent QTc prolongation (10 ms at 80 mg supratherapeutic dose in a thorough QT study) [13]

Hormonal contraceptive interactions that matter:

• CYP3A4 inducers (rifampin, phenytoin, carbamazepine, St. John's wort): reduce contraceptive efficacy, breakthrough bleeding, and pregnancy risk [3]
• Lamotrigine: OCP use reduces lamotrigine levels by approximately 50%, risking seizure breakthrough [14]
• Certain antiretrovirals: complex bidirectional interactions with EE and progestins [15]

Clinicians should perform a comprehensive medication reconciliation rather than fixating on the vardenafil/OCP pair, which carries no documented risk.

Monitoring and Patient Counseling

No special monitoring is required when vardenafil and hormonal contraceptives are used by the same patient or by sexual partners. Standard prescribing guidance for each medication applies independently.

For vardenafil, the key counseling points remain: take on an empty stomach or after a low-fat meal for optimal absorption, avoid grapefruit juice (a moderate CYP3A4 inhibitor), do not combine with nitrates under any circumstances, and seek emergency care for erections lasting longer than 4 hours [1]. The starting dose of 10 mg can be titrated to 5 mg or 20 mg based on efficacy and tolerability.

For hormonal contraceptive users, standard counseling includes consistent daily dosing for oral formulations, awareness of drug interactions that genuinely reduce efficacy (antibiotics like rifampin, not amoxicillin), and recognition of warning signs for venous thromboembolism [3]. A 2019 Cochrane review (N=7,034 across 26 trials) confirmed that common antibiotics other than rifamycins do not reduce OCP efficacy [16].

Patients who ask about this combination at the pharmacy counter or during a telehealth visit should be told directly: these two drugs do not interact. The CYP3A4 overlap is real but clinically irrelevant at the doses used in standard therapy. No published adverse event report, FDA safety communication, or pharmacokinetic study has identified a signal warranting concern.

The Bottom Line on Vardenafil and Hormonal Contraceptives

The clinical evidence is clear. Both vardenafil and hormonal contraceptives are metabolized partly by CYP3A4, but the magnitude of ethinyl estradiol's CYP3A4 inhibition (15 to 30% AUC increase for substrates) falls well below the threshold that requires vardenafil dose adjustment. No pharmacodynamic overlap exists between PDE5 inhibition and hormonal contraception. Neither drug's FDA label flags the other as an interaction. Prescribe and use each medication according to its individual labeling without modification for co-administration.